Anika Therapeutics, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
Anika is a global joint preservation company focused on osteoarthritis pain management, regenerative solutions, soft-tissue repair, and bone-preserving joint technologies. The filing covers the three months ended March 31, 2022, compared with the three months ended March 31, 2021. The company reports one operating and reportable segment.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $36.7 million | $34.3 million | Up 7% |
| Gross profit | $21.8 million | $21.0 million | Up 4% |
| Gross margin | 59% | 61% | Down 2 percentage points |
| Operating income (loss) | $(3.6) million | $1.3 million | Declined $4.8 million |
| Net income (loss) | $(2.9) million | $2.8 million | Declined $5.8 million |
| Diluted EPS | $(0.20) | $0.20 | Declined $0.40 |
| Adjusted EBITDA | $2.6 million | $4.8 million | Down $2.2 million |
| Operating cash flow | $(1.9) million | $(2.4) million | Improved $0.6 million |
- Revenue growth was led by OA Pain Management revenue of $22.7 million, up 18%. Joint Preservation and Restoration revenue was $12.1 million, down 1%, and Non-Orthopedic revenue was $1.8 million, down 34%.
- Adjusted gross profit was $23.4 million and adjusted gross margin was 64%, compared with $25.1 million and 73%, respectively, in Q1 2021.
- Research and development expense was $6.2 million, down 3%. Selling, general and administrative expense was $19.2 million, up 6%, reflecting expanded U.S. commercial and marketing capabilities.
- Cash and cash equivalents were $90.3 million at March 31, 2022, compared with $94.4 million at December 31, 2021. Working capital was $138.3 million.
- The company had no outstanding borrowings under its $75.0 million senior revolving credit facility and was in compliance with its terms. Subject to conditions, total commitments could be increased to $150.0 million.
- Total assets were $342.2 million and stockholders’ equity was $285.8 million at March 31, 2022. The filing does not report conventional long-term debt outstanding; lease liabilities totaled $18.8 million.
- Investing cash outflow was $1.3 million, primarily capital expenditures. Financing cash outflow was $0.9 million, principally employee tax withholding on vested equity awards. Cash decreased $4.1 million during the quarter.
- DePuy Synthes Mitek Sports Medicine represented 39% of total revenue, indicating significant customer concentration. The United States represented 73% of revenue.
Material changes versus the prior comparable period
- Revenue increased $2.4 million, primarily from recovery in sales volumes and ordering patterns following COVID-19 impacts.
- Gross margin declined because of unfavorable production volumes, supply-chain and staffing challenges, and higher inventory reserves. Acquisition-related amortization and inventory step-up costs reduced gross margin by approximately 5 percentage points in Q1 2022, versus 12 percentage points in Q1 2021.
- Operating results were adversely affected by the absence of the $4.8 million non-cash benefit from the reduction in contingent consideration recorded in Q1 2021.
- Net loss also reflected higher commercial spending, partially offset by increased revenue and lower research and development expense.
- Contingent consideration remained $4.3 million at March 31, 2022. Management did not expect further Parcus Medical milestones to be achieved.
- Inventory, net, decreased to $35.2 million from $36.0 million at December 31, 2021, while inventory reserves declined to approximately $6.9 million from $9.1 million.
Guidance, outlook, commentary, risks, and unusual items
- No specific revenue, earnings, margin, or other quantitative annual guidance is provided. Management states that cash on hand, expected operating cash flows, and available credit are expected to fund anticipated operating needs and continued investment.
- Management expects continued investment in research and development, clinical trials, and commercial infrastructure. The filing states that quarterly and annual results may remain affected by COVID-19, elective-procedure trends, staffing shortages, supply-chain disruptions, and distributor ordering patterns.
- COVID-19 disruptions caused product back orders or shipment delays, reduced customer access, and delayed certain clinical and research programs. The effect of future variants or restrictions remains uncertain.
- Inflation is identified as an additional risk through higher shipping, labor, and other operating costs.
- Former Parcus Medical unitholders filed an arbitration claim regarding earnout provisions. The company does not expect resolution during 2022, cannot estimate a potential liability or loss range, and intends to defend the claims.
- Adjusted EBITDA, adjusted gross profit, adjusted gross margin, adjusted net income, and adjusted EPS are non-GAAP measures. Acquisition-related amortization, inventory step-up, contingent consideration changes, and stock-based compensation are material adjustments and should be considered when evaluating these measures.
- The company reported effective disclosure controls and no material changes in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether OA Pain Management growth continues to offset weakness in Joint Preservation and Restoration and Non-Orthopedic products.
- Whether gross margin recovers as supply-chain, staffing, production-volume, and inventory-reserve pressures ease.
- The timing and potential financial exposure from the Parcus Medical earnout arbitration.
- The sustainability of operating cash generation, given negative operating cash flow in Q1 2022 and planned commercial, clinical, and capital investments.
- The company’s dependence on DePuy Synthes Mitek Sports Medicine for approximately 39% of revenue and on U.S. customers for approximately 73% of revenue.
- Progress on pipeline products, regulatory approvals, clinical trials, and commercialization plans, including products not yet available for commercial sale in the United States.
- The effect of inflation, COVID-19 developments, elective-surgery volumes, foreign currency movements, and future supply-chain disruptions.